The effects of tamoxifen on homocysteine levels in breast cancer patients

Open Medicine ◽  
2009 ◽  
Vol 4 (4) ◽  
pp. 450-453
Author(s):  
Aydan Eroğlu ◽  
Yonca Eğin ◽  
Nejat Akar
Keyword(s):  
Breast Cancer ◽  
Cancer Patients ◽  
Mthfr C677t ◽  
Breast Cancer Patients ◽  
Serum Homocysteine ◽  
Intron 1 ◽  
Increased Risk ◽  
Significant Difference ◽  
The Relationship ◽  
Control Study

AbstractTamoxifen is widely used in the treatment of breast cancer and associated with an increased risk of thromboembolism (TE). An elevated homocysteine is one of the risk factors for TE. The aim of the study was to assess the effect of tamoxifen on serum homocysteine levels in breast cancer patients. We performed a case-control study in 20 female subjects to evaluate the relationship between homocysteine levels, and 5,10-methylenetetrahyrofolate reductase (MTHFR) C677T and dihydrofolate reductase (DHFR) 19-bp intron-1 deletion polymorphisms in breast cancer patients and in control subjects. It was observed that homocysteine levels were decreased during tamoxifen therapy, but this finding was not statistically significant. There was also no statistically significant difference in homocysteine levels between the two groups (p> 0.05). MTHFR C677T and DHFR 19-bp deletion polymorphisms were not associated with serum homocysteine value in either group.

scholarly journals A comparative study of selenium concentration and glutathione peroxidase activity in normal and breast cancer patients

2009 ◽  
Vol 12 (1) ◽  
pp. 59-63 ◽  
Author(s):  
Masoumeh Moradi ◽  
Mohammad Hassan Eftekhari ◽  
Abdolrasoul Talei ◽  
Abdolreza Rajaei Fard
Keyword(s):  
Breast Cancer ◽  
Glutathione Peroxidase ◽  
Cancer Patients ◽  
Selenium Concentration ◽  
Atomic Absorption Spectrophotometry ◽  
Breast Cancer Patients ◽  
Healthy Women ◽  
Significant Difference ◽  
Gpx Activity ◽  
Control Study

AbstractObjectiveThe present study was undertaken to compare plasma Se values and glutathione peroxidase (GPX) activity in normal and breast cancer patients.DesignIn a case–control study, forty-five breast cancer patients and the same number of healthy women were randomly selected from their population. Se was measured in plasma by atomic absorption spectrophotometry and GPX activity in erythrocytes was measured using a standard spectrophotometric method.ResultsPlasma Se concentration in healthy women and breast cancer patients was in the normal range, with no statistically significant difference observed between the two groups (138·40 (sd 40·36) μg/l v. 132·15 (sd 35·37) μg/l, respectively). Erythrocyte GPX activity was significantly (P<0·01) higher in breast cancer patients (24·81 (sd 11·66) U/g Hb) compared with healthy women (20·29 (sd 4·24) U/g Hb).ConclusionThe present study indicated that Se deficiency was not a problem in the participants, and sufficient quantity of this element could increase GPX activity to have a protective effect against oxidative damage.

scholarly journals Depression and Fatigue of Breast Cancer Patients Receiving Chemotherapy during the Covid-19

2021 ◽  
Vol 3 (3) ◽  
pp. 297-304
Author(s):  
Dwi Retnaningsih ◽  
Roudhotul Auliyak ◽  
Mariyati Mariyati ◽  
Enggar Nurnaningsih
Keyword(s):  
Breast Cancer ◽  
Data Analysis ◽  
Cancer Patients ◽  
Depression Scale ◽  
Fear Of Death ◽  
Anxiety And Depression ◽  
P Value ◽  
Breast Cancer Patients ◽  
Increased Risk ◽  
The Relationship

Depression in breast cancer patients includes mental shock, inability to accept reality, hopelessness, fear of death, and fear of the future. Depression creates long periods of sadness and worry, usually accompanied by feelings of worthlessness. Fatigue is a symptom that often appears in cancer patients undergoing chemotherapy. Associated with the conditions of the COVID-19 pandemic, cancer patients have an increased risk of transmitting COVID-19 because they have decreased endurance. This study aims to determine the relationship between depression and fatigue in breast cancer patients undergoing chemotherapy at Hospital Sultan Agung Semarang Indonesia. The instruments used in this study were questionnaire of the hospitals anxiety and Depression Scale (HADS) and questionnaire of fatigue, 30 female respondents who suffer from breast cancer and have undergone chemotherapy. Rank Spearman data analysis. P value = 0.000 and correlation coefficient value r = 0.671. There is a relationship between depression and fatigue in breast cancer patients undergoing chemotherapy which has an impact on adherence to chemotherapy for breast cancer patients. The higher the level of depression is, the more severe the level of fatigue in cancer patients.

Molecular evaluation of HIF-1α gene variation and determination of its frequency, and association with Breast Cancer susceptibility in Saudi Arabia

2020 ◽  
Vol 20 ◽  
Author(s):  
Rashid Mir ◽  
Faisel M. Abu-Duhier ◽  
Ibrahim Altedlawi Albalawi
Keyword(s):  
Breast Cancer ◽  
Saudi Arabia ◽  
Cancer Patients ◽  
Genotype Distribution ◽  
Breast Cancer Patients ◽  
Data Set ◽  
Gene Variation ◽  
Increased Risk ◽  
Significant Difference ◽  
Inheritance Model

Aim: Hypoxia-inducible factor 1 (HIF-1) is responsible in regulating oxygen homeostasis in tissues. HypoxiaInducible Factor α (HIF1-α) is a central effector of the hypoxic response. HIF-1α protein overexpression has been shown to have prognostic relevance in breast cancer. HIF-1α polymorphism is associated with increased breast susceptibility reported by several case controls studies but results remained controversial. Therefore, we studied the relationship between the HIF1α gene polymorphism with the breast cancer risk in Saudi Arabia. Methods: This study was consisted of 114 histologically confirmed Breast cancer patients and 117 sex -matched healthy women. HIF-1α genotyping was done by Amplification refractory mutation system PCR method. The HIF-1α gene genotypes were correlated with different clinicopathological characteristics of breast cancer patients. Results: A significant difference was observed in genotype distribution of HIF-1α gene variation C1772T between breast cancer cases and sex matched healthy controls (p=0.001). Our findings showed that the HIF- 1α variant was associated with an increased risk of Breast cancer for HIF-1α CC vs CT genotype OR = 0. 38, 95% CI = (0. 22 -0. 65), P = 0.005) in codominant inheritance model. The significant association was reported for HIF1A for genotypes CC vs (CT+ TT) OR = 0. 39, 95% CI = (0. 231 -0. 67), P = 0.007) in dominant inheritance model tested. In case of recessive inheritance model, a significant association of HIF-1 alpha gene variants was reported for CC VS -(CC+ CT) vs TT) OR = 3.10, 95% CI = (0. 12- 77.03), P = 0.56). During the allelic comparison, A allele significantly increased the risk of Breast cancer with odd ratio (OR = 0. 66, 95% CI = 0. 53 -1. 21, P = 0.04) and risk ratio RR= 0. 51 (0. 32 -0. 80) P= 0.004). A significant association of HIF1α polymorphism was reported with stage as well as distant metastasis of the disease. Conclusion: A significant association of HIF- 1α-CT heterozygosity and T allele significantly increased the susceptibility and is associated with the metastasis of Breast cancer. Further studies with larger data set and well-designed models are required to validate our findings.

scholarly journals Inherited thrombophilic risk factors in Serbian breast cancer patients

Genetika ◽  
2019 ◽  
Vol 51 (2) ◽  
pp. 463-472
Author(s):  
Iva Pruner ◽  
Branko Tomic ◽  
Marija Dragojevic ◽  
Maja Gvozdenov ◽  
Mirjana Kovac ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Risk Factors ◽  
Cancer Patients ◽  
Cancer Susceptibility ◽  
Mthfr C677t ◽  
Control Group ◽  
Gene Variants ◽  
Breast Cancer Patients ◽  
Significant Difference

Breast cancer is the leading cause of cancer-related death among women. An increased burden of thrombotic events among breast cancer patients, leading to higher mortality and morbidity rates, is well established. There are a number of genetic risk factors associated with thrombosis, but their contribution to thrombotic tendencies in patients with cancer is not completely elucidated. We aimed to investigate possible role of FV Leiden, FII G20210A, MTHFR C677T and PAI-1 4G/5G gene variants in etiopathology of breast cancer and accompanying thrombosis in cohort of Serbian patients. Our study included 316 subject divided in three groups: breast cancer patients with (97) or without (99) accompanying thrombosis and healthy control group (120). According to our results, the prevalence for all four prothrombotic gene variants were similar in cancer patients with and without thrombosis and no statistically significant difference was observed between these groups. We detected lower frequency of MTHFR 677TT genotype in breast cancer patients when compared to control group (P=0.014; OR=0.145 (95%CI 0.031-0.679)), indicated that MTHFR C677T homozygosity could play a protective role in breast cancer susceptibility. Our study noted the lack of association between common prothrombotic gene variants and increased prothrombotic risk in Serbian breast cancer patients. Also, our results point out possible role of MTHFR 677TT genotype in etiology of breast cancer, but further studies on larger cohort of patients are needed.

scholarly journals Breast cancer survivorship and level of institutional involvement utilizing integrative oncology.

2021 ◽  
Vol 39 (15_suppl) ◽  
pp. e18588-e18588
Author(s):  
Terri Crudup ◽  
Linna Li ◽  
Jennifer Wright Dorr ◽  
Elizabeth Lawson ◽  
Rachel Stout ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Overall Survival ◽  
Cancer Patients ◽  
Metastatic Disease ◽  
Multivariate Modeling ◽  
Breast Cancer Patients ◽  
Integrative Oncology ◽  
Academic Setting ◽  
Significant Difference ◽  
The Relationship

e18588 Background: A growing body of evidence has shown that a Whole Person Integrative Oncology approach, adding the use of complementary and lifestyle therapies to cancer treatments, benefits patients by improving patient-reported outcomes and potentially extending overall survival. This study aims to investigate the relationship between the survival outcomes of breast cancer patients and the level of involvement in Integrative Oncology at the institutions treating those patients. Methods: Between January 2013 and December 2014, 4,815 breast cancer patients were available for survival analysis using an established claims-based method. These patients were filtered to include those with clear mapping to treating oncologists and treating institutions. To measure each institution’s level of Integrative involvement, a scoring system was developed with the Samueli Foundation and oncologists from each institution were surveyed on the education, availability, and financing of 12 complementary and lifestyle approaches during the treatment timeframe. Statistical analysis using multivariate modeling with logistic regression and a lasso approach were employed. 19 variables across region, patient demographics, and institutional profile were included. Model coefficients are exponentiated and presented as odds-ratios, with less than one having a negative impact on survival and greater than one improved survival. Results: We identified 173 patients mapping to 103 institutions and 103 oncologists who responded to our survey. Median age of breast cancer patients was 51 (range: 32-76). 14 of the patients (8%) were identified as metastatic. The 5-year overall survival among the Low scoring institutions was 89%, Low-Mid 96%, Mid-High 96%, High 95%. Chi square testing across these cohorts showed no statistically significant difference between them. On multivariate modeling, age, geography, metastatic status, academic setting, and Integrative score were predictors of 5-year survival. The most significant 9 variables are shown in Table. Having metastatic disease, treatment at a non NCCN designated facility, treatment at Midwest or Western Region predicts for lower 5-year survival. Older age, treatment at an academic setting, and having a High or Low-Mid Integrative score are predictors of improved survival. Conclusions: This study suggests that in addition to traditional predictors of survival such as metastatic disease and younger age, patients receiving treatment at an institution that supports Integrative Oncology programs may be associated with improved survival. More work is needed to evaluate the relationship between Integrative Oncology and cancer treatment outcomes.[Table: see text]

scholarly journals The concentration of matrix metalloproteinase 9 in the tumor and peritumoral tissue as prognostic marker in breast cancer patients

2019 ◽  
Vol 76 (5) ◽  
pp. 476-484 ◽  
Author(s):  
Danijela Cvetkovic ◽  
Bojan Milosevic ◽  
Aleksandar Cvetkovic ◽  
Srdjan Ninkovic ◽  
Jovana Jovankic ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Cancer Patients ◽  
Prognostic Marker ◽  
Clinicopathological Parameters ◽  
Cancer Tissue ◽  
Axillary Lymph ◽  
Breast Cancer Patients ◽  
Increased Risk ◽  
Significant Difference ◽  
Peritumoral Tissue

Background/Aim. Breast cancer is one of the most common malignancies among women all over the world. Tumor microenvironment represents one of the main regulators of tumorigenesis. We investigated the role of matrix metalloproteinases 9 (MMP-9) concentration in peritumoral tissue as a prognostic marker in the breast cancer patients. Methods. The ELISA test was used to determine a total MMP-9 concentration in carcinoma and peritumoral tissue sample in the patients with breast cancer. Comparison of MMP-9 protein expression with the clinicopathological parameters was evaluated. Results. Peritumoral tissue at 3 cm distance from the tumor produces more MMP-9 than the tumor itself. The ratio of concentrations of MMP-9 in the tumor and peritumoral tissue considerably changes in favor of peritumoral tissue with the increase of tumor size and the involvement of axillary lymph nodes. In N0 stage, the concentration ratio of MMP-9 in the tumor and peritumoral tissues was 1 : 1.44, but in the N2 stage, the ratio was 1 : 26.5. Conclusion. In patients with breast cancer even in an early stadium there is a change in MMP-9 concentration in peritumoral tissue. We can extract the group of patients at increased risk for the development of lymph node metastasis. A statistically significant difference between the concentrations of MMP-9 in the peritumoral tissue and cancer tissue exists only in case of metastatic disease not in MO stadium implying need for early detection of still unknown metastases in such patients.

scholarly journals LAPTM4B Gene Expression And Polymorphism As Diagnostic Markers Of Breast Cancer In Egyptian Patients

2015 ◽  
Vol 34 (4) ◽  
pp. 393-401 ◽  
Author(s):  
Olfat Shaker ◽  
Fatma Taha ◽  
Maha Salah ◽  
Mohamed El-Marzouky
Keyword(s):  
Breast Cancer ◽  
Serum Level ◽  
Cancer Patients ◽  
Case Control Study ◽  
Breast Cancer Patients ◽  
Large Tumor ◽  
Significant Difference ◽  
Egyptian Patients ◽  
Control Study

Summary Background: The aim of this study was to investigate the association between LAPTM4B gene polymorphism and the risk of breast cancer among Egyptian female patients. Also, measurement was done of its serum level to evaluate its significance as a diagnostic marker for breast cancer. Methods: This case control study was done on 88 breast cancer patients, 40 with fibroadenoma and 80 healthy subjects. Genotyping of the LAPTM4B polymorphism was determined by PCR. Serum LAPTM4B level was measured using ELISA. Results: There was a significant difference in the (*1/2+ *2/2) genotypes in breast cancer patients (59.1) compared to the control subjects (43.8%) (P=0.047; OR=1.86; 95% CI=1.01–3.43). The frequency of the allele 2* of the LAPTM4B gene was significantly higher in breast cancer patients (36.4%) than in the control (25.6%) (p=0.034; OR=1.66; 95% CI=1.04–2.65). Genotypes (*1/2+*2/2) were significantly associated with the differential classification of TNM. Serum level of LAPTM4B was significantly higher in breast cancer patients than in control and fibroadenoma and in fibroadenoma patients than in control. In breast cancer patients, serum LAPTM4B was significantly higher in stage III and in large tumor size. Serum LAPTM4B was significantly higher in the cancer patients’ genotypes (*1/2+*2/2). Conclusions: Genetic polymorphism of LAPTM4B is a potential risk factor for the development of breast cancer. Serum LAPTM4B may be used as a diagnostic and prognostic marker for breast cancer.

scholarly journals Lack of Association between LCS6 Variant in KRAS Gene with the Occurrence of Breast Tumors in Iraqi Women

2020 ◽  
Vol 17 (2) ◽  
pp. 0426
Author(s):  
Roya Al-Haddad et al.
Keyword(s):  
Breast Cancer ◽  
Cancer Patients ◽  
Breast Cancer Patients ◽  
Specific Primers ◽  
Kras Gene ◽  
Increased Risk ◽  
Pcr Products ◽  
Iraqi Women ◽  
Control Study ◽  
Related Mortality

Breast cancer is the most commonly diagnosed cancer and remains one of the main reasons of cancer-related mortality in women worldwide. KRAS variant rs61764370 (T>G) is associated with an increased risk of occurrence of many cancers, Here The case-control study was accomplished on 135 women including 45 women with breast cancer patients, 45 women with benign breast lesions and 45 healthy women to analyze the association of KRAS variant rs (61764370 T>G) with breast cancer. LCS 6 variant in KRAS gene was amplified by using specific primers, then genotype was detected after sequencing the PCR products. The results showed that the genotype and allele frequency of TT and GT allele of  KRAS gene were statistically non-significant (p< 0.01) among breast cancer patients and breast benign lesions compared with healthy controls in Iraqi women.

Relationship and prognosis of hospho-Akt and CD44v6 in breast cancer

2009 ◽  
Vol 27 (15_suppl) ◽  
pp. 1126-1126
Author(s):  
P. Yu ◽  
L. Zhou ◽  
K. Song ◽  
K. Li
Keyword(s):  
Breast Cancer ◽  
Treatment Outcome ◽  
Lymph Node ◽  
Cancer Patients ◽  
Breast Cancer Patients ◽  
Node Negative ◽  
Significant Difference ◽  
Cancer Tissues ◽  
The Relationship ◽  
Cd44v6 Expression

1126 Background: The purpose of this study was to investigate the relationship between pAkt and CD44v6 expression of breast cancer after surgery. We also evaluated the expression patterns and predictive value of pAKT and CD44v6 in breast cancer tissues. Methods: Expression of pAkt and CD44v6 protein was detected using immunohistochemistry in 98 patients. The correlation between the expression of pAkt, CD44v6, and other disease-related characteristics with treatment outcome was investigated. Kaplan-Meier survival analysis and Cox regression were used to observe the correlation between variables and the prognostic value. Results: Of all these 98 cases, 37 cases (37.8%) were observed as positive for pAkt expression, and there were 25 cases (51.0%) pAKT positive expression in the lymph node (+) and 15 (30.6%) in lymph node (-) of 49 cases. pAkt expression had no significant difference in node-positive group and node-negative group. We examined the relationship between pAKT and HER2 expression, pAkt expression was positively correlated with HER-2 expression (p = 0.009). A statistically significant difference in positive staining for pAkt was observed between CD44V6-positive and CD44V6-negative tumors (p = 0.016). CD44v6 positive tumors showed a statistically very highly significant association between node-positive and node-negative (p = 0.013). For prognosis value, a week relationship was observed between pAkt and OS, but DFS was inversely associated with pAkt staining intensity (p = 0.061, p = 0.004). There had a statistical correlation between CD44v6 overexpression and OS and DFS (p = 0.026 and 0.006 respectively). Univariate analysis revealed that lymph node status and CD44V6 were significantly associated with decreased OS and DFS, but there had no significant difference between variables and OS and DFS by multivariate analysis. Conclusions: Our data suggested that there had a intensive relationship between pAKT and CD44v6 expression in breast cancer tissues. We demonstrated that both pAkt and CD44v6 were significantly assiociated with a decreased OS and DFS in breast cancer patients. pAKT and CD44v6 overexpressed in cancer cells may be sensitive markers for predicting the treatment outcome in breast cancer patients. No significant financial relationships to disclose.

Sign in / Sign up

Export Citation Format

Share Document